Format

Send to

Choose Destination
AIDS. 2018 Jan 2;32(1):121-125. doi: 10.1097/QAD.0000000000001679.

Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors.

Author information

1
Grupo de Virología Clínica.
2
Servicio de Farmacia.
3
Unidad de Epidemiología Clínica y Bioestadística, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC).
4
Infectious Diseases Service and 'Fight AIDS' Foundation, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.

Abstract

: HIV-1 subtype B (54.4%) and subtype F (27.2%) are the most prevalent variants in patients who started antiretroviral therapy including an integrase inhibitor in the last 2 years in Northwest Spain. Virological response rates to antiretroviral therapy based on integrase inhibitor were significantly lower among F subtypes compared with B subtypes at weeks 12 (25.0% vs. 75.0%) and 24 (59.1% vs. 95.0%). Subtype F was independently associated with virological response at 24 weeks [odds ratio 11.8 (95% confidence interval 1.1-119.9); P = 0.037].

PMID:
29112068
DOI:
10.1097/QAD.0000000000001679
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center